ES2100965T3 - Antagonistas de lhrh. - Google Patents

Antagonistas de lhrh.

Info

Publication number
ES2100965T3
ES2100965T3 ES91919435T ES91919435T ES2100965T3 ES 2100965 T3 ES2100965 T3 ES 2100965T3 ES 91919435 T ES91919435 T ES 91919435T ES 91919435 T ES91919435 T ES 91919435T ES 2100965 T3 ES2100965 T3 ES 2100965T3
Authority
ES
Spain
Prior art keywords
mother
nac
activity
lhrh antagonists
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91919435T
Other languages
English (en)
Inventor
Shaobo Xiao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Asta Medica GmbH
Original Assignee
Asta Medica GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asta Medica GmbH filed Critical Asta Medica GmbH
Application granted granted Critical
Publication of ES2100965T3 publication Critical patent/ES2100965T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Preparation (AREA)

Abstract

EL INVENTO CONSTA DE DOS ASPECTOS: 1) EL METODO DE DISEÑO Y SINTESIS DE LOS ANTAGONISTAS LHRH; 2) LOS PRODUCTOS QUE SE OBTIENEN POR LA UTILIZACION DE ESTE METODO. TOMANDO COMO COMPONENTE MADRE (NAC LEU7, ARG3, PRO9, DALA10) NH2. POR LA MODIFICACION DE LAS DOS ZONAS ALCALINA Y LIPOPHLICA DE LA MOLECULA DEL COMPUESTO MADRE SE OBTIENEN UNA SERIE DE EQUIVALENTES NUEVOS, QUE SE EXPRESAN COMO (NAC DALA 10)NH2. DE ESTA FORMA LA ALTA ACTIVIDAD OVOLAROTIA DEL COMPUESTO MADRE (SE OBTIENE) A LA VEZ QUE SE REDUCE LA ACTIVIDAD LIBERATORIA DE LA HISTAMINA HASTA UNOS NIVELES MEDICAMENTE ACEPTABLES.
ES91919435T 1990-11-10 1991-11-08 Antagonistas de lhrh. Expired - Lifetime ES2100965T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN90108955A CN1036343C (zh) 1990-11-10 1990-11-10 新促黄体生成素释放激素拮抗类似物的制备方法

Publications (1)

Publication Number Publication Date
ES2100965T3 true ES2100965T3 (es) 1997-07-01

Family

ID=4881223

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91919435T Expired - Lifetime ES2100965T3 (es) 1990-11-10 1991-11-08 Antagonistas de lhrh.

Country Status (29)

Country Link
EP (1) EP0564466B1 (es)
KR (1) KR100244624B1 (es)
CN (1) CN1036343C (es)
AT (1) ATE149520T1 (es)
AU (1) AU662496B2 (es)
CA (1) CA2095932C (es)
CZ (1) CZ284168B6 (es)
DE (1) DE69125024T2 (es)
DK (1) DK0564466T3 (es)
EE (1) EE03141B1 (es)
ES (1) ES2100965T3 (es)
FI (1) FI933156A7 (es)
GR (1) GR3023389T3 (es)
HR (1) HRP920585B1 (es)
IE (1) IE913915A1 (es)
LT (1) LT3971B (es)
LV (1) LV10106B (es)
NO (1) NO931697L (es)
NZ (1) NZ240505A (es)
PH (1) PH31178A (es)
PL (1) PL170564B1 (es)
PT (1) PT99458B (es)
RU (1) RU2123499C1 (es)
SI (1) SI9111779B (es)
SK (1) SK281319B6 (es)
UA (1) UA41300C2 (es)
WO (1) WO1992008733A1 (es)
YU (1) YU48831B (es)
ZA (1) ZA918847B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2136079A1 (en) * 1992-12-18 1994-07-07 Fortuna Haviv Lhrh antagonists having modified aminoacyl residues at positions 5 and 6
DE4305225A1 (de) * 1993-02-19 1994-08-25 Asta Medica Ag Neues Herstellverfahren für Cetrorelix Lyophilisat
US6828415B2 (en) 1993-02-19 2004-12-07 Zentaris Gmbh Oligopeptide lyophilisate, their preparation and use
DE4338015A1 (de) * 1993-11-08 1995-05-11 Asta Medica Ag Verwendung von D-glucopyranuronsäuren und deren Derivaten zum Einbau in pharmakologisch wirksame Peptide und deren Salze
US5843901A (en) * 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
DE19544212A1 (de) * 1995-11-28 1997-06-05 Asta Medica Ag Neue LH-RH-Antagonisten mit verbesserter Wirkung
US5968547A (en) 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
DE19911771B4 (de) * 1999-03-17 2006-03-30 Zentaris Gmbh LHRH-Antagonist, Verfahren zu seiner Herstellung und seiner Verwendung
CN101037472B (zh) * 2006-03-14 2013-03-27 中国人民解放军军事医学科学院毒物药物研究所 具有低组胺释放作用的促黄体生成素释放激素拮抗剂
CN102675418B (zh) * 2011-03-15 2016-04-20 中国人民解放军军事医学科学院毒物药物研究所 Lhrh拮抗剂衍生物、其制备方法及用途
CN103524599B (zh) * 2012-07-05 2016-04-20 中国人民解放军军事医学科学院毒物药物研究所 环肽lhrh拮抗剂衍生物及其药物用途
CN104418936B (zh) * 2013-08-20 2018-06-05 中国人民解放军军事医学科学院毒物药物研究所 Lhrh拮抗剂衍生物及其药物用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4801577A (en) * 1987-02-05 1989-01-31 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide analogs of LHRH useful as LHRH antagonists
US4851385A (en) * 1987-07-15 1989-07-25 Indiana University Foundation LHRH antagonist analogs having low histamine-release activity

Also Published As

Publication number Publication date
YU177991A (sh) 1994-06-24
NZ240505A (en) 1993-04-28
IE913915A1 (en) 1992-05-20
RU2123499C1 (ru) 1998-12-20
EP0564466A1 (en) 1993-10-13
HRP920585A2 (en) 1997-04-30
CA2095932C (en) 2003-02-25
PT99458A (pt) 1992-10-30
EE03141B1 (et) 1998-12-15
DE69125024T2 (de) 1997-07-17
CN1061605A (zh) 1992-06-03
FI933156A0 (fi) 1993-07-09
GR3023389T3 (en) 1997-08-29
ZA918847B (en) 1992-08-26
FI933156A7 (fi) 1993-07-09
WO1992008733A1 (en) 1992-05-29
LV10106B (en) 1995-04-20
DK0564466T3 (da) 1997-08-25
SK45393A3 (en) 1993-10-06
KR100244624B1 (ko) 2000-02-15
CN1036343C (zh) 1997-11-05
PL170564B1 (pl) 1996-12-31
NO931697D0 (no) 1993-05-10
YU48831B (sh) 2002-03-18
KR930703353A (ko) 1993-11-29
SI9111779A (en) 1997-04-30
SK281319B6 (sk) 2001-02-12
EP0564466B1 (en) 1997-03-05
LT3971B (en) 1996-05-27
HRP920585B1 (en) 2000-08-31
SI9111779B (en) 2001-12-31
LTIP1513A (en) 1995-06-26
PL295427A1 (en) 1993-09-06
CA2095932A1 (en) 1992-05-11
CZ84893A3 (en) 1994-02-16
CZ284168B6 (cs) 1998-09-16
NO931697L (no) 1993-07-07
PH31178A (en) 1998-03-20
LV10106A (lv) 1994-05-10
PT99458B (pt) 1999-02-26
UA41300C2 (uk) 2001-09-17
ATE149520T1 (de) 1997-03-15
AU8861291A (en) 1992-06-11
AU662496B2 (en) 1995-09-07
DE69125024D1 (de) 1997-04-10

Similar Documents

Publication Publication Date Title
ES2100965T3 (es) Antagonistas de lhrh.
TR200102020T2 (tr) Raf kinaz inhibitörleri olarak w-karboksiaril sübstitüe edilmiş difenil üreler.
DE69012575D1 (de) Auf hydroxaminsäure basierte kollagenaseinhibitoren.
CO4290424A1 (es) Pirazolopiridinas, pirrolopiridinas, composiciones farmaceu- ticas que las contienen y procedimientos para su administra- cion como antagonista del factor de liberacion de cortico- tropina
MA29742B1 (fr) Derives de benzoquinazoline et utilisation de ceux-ci dans le traitement de maladies osseuses
UY27774A1 (es) Inhibidores de metaloproteinas de triaril-oxi-aril-espiropirimidina-2,4,6-triona
PA8578601A1 (es) Derivados de 2,2- difenil-benzodioxol
CL2004000382A1 (es) Tetrahidroisoquinolinas sustituidas, proceso de preparacion, y composicion farmaceutica, utiles en el tratamiento y prevencion de estados patologicos que se alivian con un agonista de 5-ht6.
BR0313747A (pt) Inibidores de transcriptase reversa de não-nucleosìdeo
DE60319066D1 (de) 1,4-disubstituierte benzokondensierte cycloalkyl-harnstoffverbindungen zur behandlung von zytokinvermittelten erkrankungen
ES2192213T3 (es) Arilalquil-diazinonas como inhibidores de fosfodiesterasa iv.
GT200000183A (es) Aminoacidos biciclicos como agentes farmaceuticos.
CO5271715A1 (es) 7-aza-indolin-2-onas sustituidas en 4 y su uso como inhibidores de proteiuna quinasa
CY1109880T1 (el) ΑΝΤΑΓΩΝΙΣΤΗΣ CaSR
CY1121474T1 (el) Συνδυασμος αντιϊικων παραγοντων αμεσης δρασης και ριμπαβιρινης για την θεραπευτικη αγωγη ασθενων me hcv
CY1109037T1 (el) Πιπεραζινες χρησιμες για θεραπεια πονου
CL2004000590A1 (es) Compuestos derivados de 1,3,4-oxadiazol-3-ona, 1,3,4-tiadiazol-2-ona y de 1,2,4-triazol-3-ona; composicion farmaceutica que los contiene; procedimiento de preparacion y su uso en la preparacion de un medicamento en los que esta relacionado el virus v
DK261490D0 (da) New pharmaceutical compound
EA200400548A1 (ru) Лечение тяжёлой пневмонии путём введения ингибитора пути тканевого фактора (tfpi)
BR0209645A (pt) Oxazolo- e furopirimidinas e seu uso como medicamentos
DK1458393T3 (da) Substituerede diketopiperaziner som oxytocinantagonister
AR041942A1 (es) Derivados de 10-oxa -1-aza-dibenzo [a,d] ciclohepteno-7-carboxilico como antagonistas ccr1 para el tratamiento de la enfermedad desmielinizante inflamatoria
MX9205123A (es) Derivados de 5-hidroxi-2-pirimidinilmetileno utiles como agentes anti-inflamatorios.
ES2091712B1 (es) Asociaciones sinergizantes que tienen un efecto antagonista de los receptores nk1 y nk2.
AR131919A1 (es) Compuestos sustituidos de pirazolopirimidina y su uso médico

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 564466

Country of ref document: ES